A Phase 2/3 interventional study of PP405 0.05% Topical Gel and Vehicle Topical Gel in Androgenetic Alopecia, sponsored by Pelage Pharmaceuticals, Inc.. Recruiting at 63 sites in 2 countries. Open to male participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Pelage Pharmaceuticals, Inc. · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 216 studies in Alopecia with a site in United States — 43 open to participants now, 63 under way, 6 of them phase 3. Alopecia · United States.
Among the 216 studies in Alopecia with a site in United States, this one is the 7th largest by planned enrollment of the 203 interventional ones that give a count, is one of 14 that started in 2026, is one of 3 in phase 2/3, reaches primary completion later than 49 of the 62 other live ones, and was the 214th registered.
512 studies on the registry are indexed under Alopecia; 129 are open to participants now.
Browse Alopecia studies →43 of the 216 studies in Alopecia with a site in United States are open now. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 18–80
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+
University of Miami · Sites in United States
Ages 18+
K. Kay Durairaj, MD, FACS, A Medical Corporation · Sites in United States
Ages 35–55 · Women only
Charles Mays · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 75 Alopecia studies recruiting now, 25 (33%) set no upper age limit and 46 (61%) stop at 75 or younger; 9 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 55 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
216 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 38 · Phase 2 57 · Phase 3 17 · Phase 4 9
First in 2000; this study’s year is marked. 14 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 600 is above the median of 50 across 431 interventional studies indexed under Alopecia.
Median enrollment 40 across the 203 interventional studies, 204 across the 12 observational. Of the 126 that completed or were terminated, 52 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
123 of 216 have an industry lead sponsor. The 10 most frequent:
Pelage Pharmaceuticals, Inc. is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Pelage Pharmaceuticals, Inc. has 3 studies filed under Alopecia — fewer than ten, so there is no comparison to draw.
28 of the studies in Alopecia with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06972264Phase 3Veradermics, Inc.Safety and Efficacy of VDPHL01 in Males With AGA | 2026-12 |
| NCT07146022Phase 3Veradermics, Inc.Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA) | 2027-06 |
| NCT04207931Wake Forest University Health SciencesTreatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study | 2026-11 |
| NCT05416333Wake Forest University Health SciencesAzelaic Acid as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA) | 2026-11 |
| NCT07588243CynosureLutronicA Clinical Study to Evaluate the Efficacy and Safety of Ultra in Promoting Hair Regrowth | 2026-12 |
Add all 28 to your calendar (.ics) → With an account.
Among the 216 studies in Alopecia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study is designed to validate efficacy and long term safety of PP405.
Participants will initially be randomized 1:1 to PP405 or vehicle and complete a 24 week double blinded treatment period. At Week 24, the PP405 group will continue PP405 treatment, and the vehicle group will be re-randomized 1:1 to PP405 or vehicle for the double-blind long term safety extension period through study week 52.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PP405 applied to the scalp from Day 1 to Week 24; then continuing PP405 from Week 24 to Week 52.
Drug: PP405 0.05% Topical Gel
Vehicle applied to the scalp from Day 1 to Week 24; then re-randomized 1:1 to receive either PP405 or vehicle QD from Week 24 to Week 52
Drug: PP405 0.05% Topical Gel · Drug: Vehicle Topical Gel
Medicated topical gel containing PP405 0.05%
Also known as: PP405
Topical gel
Also known as: Vehicle
Change from baseline in non-vellus target area hair count
Change from baseline in non-vellus target area hair count (nvTAHC) at the vertex
Time frame: Week 24
Change from baseline in the Participant Assessment of Scalp Coverage
Change from baseline in the Participant Assessment of Scalp Coverage (PASC), where higher scores correspond to greater coverage
Time frame: Week 24
≥20% increase from baseline in non-vellus target area hair count
Proportion of participants with ≥20% increase from baseline in non-vellus target area hair count
Time frame: week 24
Change from baseline in non-vellus target area hair count
Change from baseline in non-vellus target area hair count (nvTAHC) at the vertex
Time frame: Week 12
Change from baseline in the Participant Assessment of Scalp Coverage
Change from baseline in the Participant Assessment of Scalp Coverage (PASC), where higher scores correspond to greater coverage
Time frame: Week 12
≥20% increase from baseline in non-vellus target area hair count
Proportion of participants with ≥20% increase from baseline in non-vellus target area hair count
Time frame: week 12
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Dec 2027, 15 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: JXL-069
Pelage Pharmaceuticals, Inc.